3-(alpha-l-arabinopyranosyl)-1-methyl-1-nitrosourea has been researched along with camptothecin in 3 studies
| Studies (3-(alpha-l-arabinopyranosyl)-1-methyl-1-nitrosourea) | Trials (3-(alpha-l-arabinopyranosyl)-1-methyl-1-nitrosourea) | Recent Studies (post-2010) (3-(alpha-l-arabinopyranosyl)-1-methyl-1-nitrosourea) | Studies (camptothecin) | Trials (camptothecin) | Recent Studies (post-2010) (camptothecin) |
|---|---|---|---|---|---|
| 6 | 1 | 1 | 13,002 | 2,229 | 5,391 |
| Protein | Taxonomy | 3-(alpha-l-arabinopyranosyl)-1-methyl-1-nitrosourea (IC50) | camptothecin (IC50) |
|---|---|---|---|
| Histone deacetylase 3 | Homo sapiens (human) | 0.05 | |
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | 7.4 | |
| DNA topoisomerase 1 | Homo sapiens (human) | 1.9799 | |
| Somatostatin receptor type 1 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 2 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 4 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 3 | Homo sapiens (human) | 0.0022 | |
| Somatostatin receptor type 5 | Homo sapiens (human) | 0.0022 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.97 | |
| Histone deacetylase 4 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 1 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 7 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 2 | Homo sapiens (human) | 0.05 | |
| Polyamine deacetylase HDAC10 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 11 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 8 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 6 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 9 | Homo sapiens (human) | 0.05 | |
| Histone deacetylase 5 | Homo sapiens (human) | 0.05 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gorbunova, VA; Kuz'minov, AE; Naskhletashvili, DR | 1 |
| Lesnaia, NA; Pokrovskiĭ, VS; Romanenko, VI; Treshchalina, EM | 1 |
| Bodiagin, DA; Pokrovskiĭ, VS; Treshchalin, MI; Treshchalina, EM | 1 |
1 review(s) available for 3-(alpha-l-arabinopyranosyl)-1-methyl-1-nitrosourea and camptothecin
| Article | Year |
|---|---|
[Combination chemotherapy with newly-developed cytostatics for disseminated small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials, Phase II as Topic; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Female; Glycosides; Humans; Irinotecan; Lung Neoplasms; Male; Methylnitrosourea; Middle Aged; Taxoids; Treatment Outcome | 2007 |
2 other study(ies) available for 3-(alpha-l-arabinopyranosyl)-1-methyl-1-nitrosourea and camptothecin
| Article | Year |
|---|---|
[Pre-clinical study of combined aranosa, cisplatin and irinotecan in the treatment of experimental lung cancer].
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Lewis Lung; Cisplatin; Drug Administration Schedule; Glycosides; Irinotecan; Male; Methylnitrosourea; Mice; Mice, Inbred C57BL; Mice, Inbred Strains | 2009 |
[Hematological toxicity of some combined chemotherapy schemes involving aranoza].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Etoposide; Glycosides; Hematologic Tests; Irinotecan; Lymphopenia; Male; Methylnitrosourea; Mice; Mice, Inbred BALB C; Neutropenia; Topotecan | 2010 |